Feature | November 30, 2012

Increased Risk Associated with Premature Cessation of Dual Antiplatelet Therapy Due to Patient Non-Adherence, Not Physician-Recommendation

Results of the PARIS Registry reported at TCT 2012

November 30, 2012 — A large observational study found the increased risk associated with dual antiplatelet therapy cessation after percutaneous coronary intervention (PCI) is tied to patient non-adherence, as opposed to physician-recommended discontinuation. Results of the PARIS registry were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Dual antiplatelet therapy (DAPT), using aspirin and a second anticlotting medication, is recommended to reduce the risk of blood clots following the implantation of a stent. Current guidelines recommend 30 days DAPT following placement of a bare-metal (BMS) stent and one year following placement of a drug-eluting stent (DES).

The PARIS Registry was a multicenter, observational study of 5,033 patients receiving PCI with stents. In this study, DAPT cessation was uniquely categorized due to the specific reasons for discontinuation (for example, due to physician recommendations versus patient non-adherence for other reasons). Using these data, researchers examined the association between DAPT use and subsequent major adverse cardiovascular events (MACE).

Among patients stopping DAPT at one year, most (approximately 62 percent) were classified as non-adherent by the pre-specified PARIS criteria. The incidence of MACE at one-year was higher in non-adherent patients than in those who discontinued therapy on physician recommendation (13.7 percent vs. 6.5 percent, p=<0.001). Those patients who remained on DAPT had a similar rate of adverse events as those who discontinued therapy on physician recommendation (6.5 percent). The PARIS investigators also observed that DAPT cessation within one year was associated with an increased risk for all adverse events, an association that was strongest in the first seven days and lessened after 30 days.

“Results of the PARIS registry indicate that the increased risk associated with DAPT cessation is entirely attributable to non-adherence as physician-guided discontinuation did not increase adverse events,” said the lead investigator, Roxana Mehran, M.D. Mehran is professor of Medicine at Mount Sinai School of Medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute. She also serves as chief scientific officer of the CRF Clinical Trials Center.

“These findings suggest that the risks associated with DAPT cessation following PCI are not uniform and varies by underlying mode, a novel finding that might influence practice patterns and risk assessment in post-PCI patients stopping DAPT,” said Mehran.

For more information: www.crf.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init